CytomX Therapeutics, Inc. (CTMX)
| Market Cap | 785.91M +1,196.9% |
| Revenue (ttm) | 35.54M -75.9% |
| Net Income | -62.14M |
| EPS | -0.39 |
| Shares Out | 217.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,923,961 |
| Open | 3.720 |
| Previous Close | 3.780 |
| Day's Range | 3.580 - 3.730 |
| 52-Week Range | 1.720 - 8.210 |
| Beta | 2.17 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+218.56%) |
| Earnings Date | May 7, 2026 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclin... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 218.56% from the latest price.
News
CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $17 and keeps a Buy rating on the shares. The firm cites the company’s financing-related dilution…
CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)
Reports Q1 revenue $10.26M, consensus $4.68M. “CytomX has continued to gain tremendous momentum in 2026 and we remain highly focused on executing against the multiple layers of potential value creatio...
CytomX Therapeutics Earnings Call Transcript: Q1 2026
Strong clinical progress for Varseta-M in late-line CRC, robust cash position, and focused capital allocation support advancement into pivotal studies. Next major data update expected in the second half of 2026, with expansion into new indications and combinations underway.
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in ...
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wi...
CytomX Therapeutics participates in a conference call with JPMorgan
JPMorgan holds a conference call to address the Top-10 questions with management on April 13 at 11:30 am. Webcast Link
CytomX Therapeutics price target raised to $12 from $10 at Piper Sandler
Piper Sandler raised the firm’s price target on CytomX Therapeutics (CTMX) to $12 from $10 and keeps an Overweight rating on the shares. Updated Phase I data on varsetatug maseatecan…
CytomX Therapeutics price target raised to $16 from $10 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $16 from $10 and keeps an Overweight rating on the shares. The firm believes the CX-2051…
CytomX Therapeutics price target raised to $16 from $8 at Jefferies
Jefferies raised the firm’s price target on CytomX Therapeutics (CTMX) to $16 from $8 and keeps a Buy rating on the shares following the “impressive” Phase 1 Varseta-M data update…
CytomX Therapeutics price target raised to $15 from $10 at Guggenheim
Guggenheim raised the firm’s price target on CytomX Therapeutics (CTMX) to $15 from $10 and keeps a Buy rating on the shares. The firm, which is updating its model and…
CytomX Therapeutics 45.9M share Secondary priced at $5.30
Jefferies, Piper Sandler, Cantor Fitzgerald and Barclays acted as joint book running managers for the offering.
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing...
CytomX Therapeutics price target raised to $11 from $6 at Wedbush
Wedbush raised the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $6 and keeps an Outperform rating on the shares. The firm notes the company announced updated expansion…
CytomX Therapeutics announces $250M common stock offering
CytomX Therapeutics (CTMX) announced that it has commenced an underwritten public offering of $250M of shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants.
CytomX Therapeutics files automatic mixed securities shelf
16:03 EDT CytomX Therapeutics (CTMX) files automatic mixed securities shelf
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has...
CytomX Therapeutics price target raised to $17 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on CytomX Therapeutics (CTMX) to $17 from $10 and keeps a Buy rating on the shares, stating that the company sets a “new…
CytomX Therapeutics upgraded to Overweight at JPMorgan after late-line CRC data
As previously reported, JPMorgan analyst Anupam Rama upgraded CytomX Therapeutics (CTMX) to Overweight from Neutral with a price target of $12, up from $7, following positive results from the Phase…
CytomX Therapeutics upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded CytomX Therapeutics (CTMX) to Overweight from Neutral with a price target of $12, up from $7.
CytomX Therapeutics price target raised to $12 from $10 at Oppenheimer
Oppenheimer raised the firm’s price target on CytomX Therapeutics (CTMX) to $12 from $10 and keeps an Outperform rating on the shares. The updated expansion data for CX-2051 “handily exceeded…
Options Volatility and Implied Earnings Moves Today, March 16, 2026
Today, several major companies are expected to report earnings: Agenus (AGEN), Assertio Therapeutics (ASRT), Dollar Tree (DLTR), Ocean Power Technologies (OPTT), Semtech (SMTC), CytomX Therapeutics (C...
CytomX Therapeutics Earnings Call Transcript: Q4 2025
Varseta-M showed strong efficacy and improved safety in late-line CRC, with ORR up to 32% and median PFS over 7 months. Dose optimization and dual prophylaxis reduced grade 3 diarrhea to 10%. Registrational studies and expansion into new indications are planned.
CytomX Therapeutics announces Phase 1 expansion data on varsetatug masetecan
CytomX Therapeutics (CTMX) announced Phase 1 expansion data for its EpCAM PROBODY(R) ADC, varsetatug masetecan in late-line metastatic CRC. The preliminary data are as of a January 16, 2026 data…
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - ...